Collegium Pharmaceutical Inc (COLL)vsUnited Therapeutics Corporation (UTHR)
COLL
Collegium Pharmaceutical Inc
$24.95
+0.56%
HEALTHCARE · Cap: $770.98M
UTHR
United Therapeutics Corporation
$593.31
-0.39%
HEALTHCARE · Cap: $25.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 291% more annual revenue ($3.19B vs $815.19M). UTHR leads profitability with a 38.6% profit margin vs 4.7%. COLL appears more attractively valued with a PEG of 0.72. COLL earns a higher WallStSmart Score of 58/100 (C).
COLL
Buy58
out of 100
Grade: C
UTHR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$384.11
Current Price
$24.95
$359.16 discount
Margin of Safety
+2.4%
Fair Value
$487.71
Current Price
$593.31
$105.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Keeps 39 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.0%
Areas to Watch
3.3% revenue growth
Smaller company, higher risk/reward
4.7% margin — thin
Earnings declined 29.0%
Expensive relative to growth rate
4.1% revenue growth
Earnings declined 20.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.
Bear Case : COLL
The primary concerns for COLL are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 4.7% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
COLL carries more volatility with a beta of 0.73 — expect wider price swings.
UTHR is growing revenue faster at 4.1% — sustainability is the question.
UTHR generates stronger free cash flow (126M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
COLL scores higher overall (58/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?